PriceTargets.com logo

XOMA Royalty - XOMA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $60.60
  • Forecasted Upside: 136.17%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$25.66 As of 01/30/2026 05:00 PM ET
▲ +0.69 (2.76%)

This chart shows the closing price for XOMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New XOMA Royalty Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XOMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XOMA

Analyst Price Target is $60.60
▲ +136.17% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for XOMA Royalty in the last 3 months. The average price target is $60.60, with a high forecast of $97.00 and a low forecast of $35.00. The average price target represents a 136.17% upside from the last price of $25.66.

This chart shows the closing price for XOMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in XOMA Royalty. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/29/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
12/22/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
12/15/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
12/12/2025Stifel NicolausSet Target$50.00
12/12/2025BenchmarkReiterated RatingBuy ➝ Buy
12/11/2025HC WainwrightLower TargetBuy ➝ Buy$104.00 ➝ $97.00
12/11/2025Leerink PartnersLower TargetOutperform ➝ Outperform$58.00 ➝ $45.00
12/9/2025UBS GroupSet Target$76.00
12/8/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/25/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/18/2025Zacks ResearchDowngradeHold ➝ Strong Sell
11/13/2025Weiss RatingsUpgradeSell (D-) ➝ Hold (C-)
10/20/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/10/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
8/12/2025Zacks ResearchUpgradeHold
5/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$104.00
4/17/2025BenchmarkInitiated CoverageBuy$35.00
3/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
2/3/2025HC WainwrightLower TargetBuy ➝ Buy$123.00 ➝ $104.00
1/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$123.00 ➝ $123.00
12/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$123.00 ➝ $123.00
12/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$117.00 ➝ $123.00
10/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$117.00 ➝ $117.00
9/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$117.00 ➝ $117.00
8/15/2024HC WainwrightBoost TargetBuy ➝ Buy$74.00 ➝ $117.00
7/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00 ➝ $74.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00 ➝ $74.00
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00
4/29/2024Leerink PartnersReiterated RatingOutperform
4/29/2024Leerink PartnersInitiated CoverageOutperform$40.00
4/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00
2/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00
12/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$74.00
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$74.00
8/9/2023HC WainwrightBoost TargetBuy ➝ Buy$69.00 ➝ $74.00
3/10/2023HC WainwrightReiterated RatingBuy$69.00
5/2/2022HC WainwrightReiterated RatingBuy$69.00
10/8/2021HC WainwrightBoost TargetBuy$56.00 ➝ $69.00
9/9/2021AegisLower TargetBuy$60.00 ➝ $56.00
9/7/2021WedbushDowngradeOutperform ➝ Neutral$22.00
6/29/2021AegisInitiated CoverageBuy$60.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 1 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 12 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 10 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 13 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
1/3/2026
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

XOMA Royalty logo
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $25.66
Low: $24.34
High: $25.76

50 Day Range

MA: $27.76
Low: $24.66
High: $34.36

52 Week Range

Now: $25.66
Low: $18.35
High: $39.92

Volume

274,454 shs

Average Volume

795,225 shs

Market Capitalization

$317.67 million

P/E Ratio

34.68

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of XOMA Royalty?

The following sell-side analysts have issued reports on XOMA Royalty in the last twelve months: Benchmark Co., HC Wainwright, Leerink Partners, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for XOMA.

What is the current price target for XOMA Royalty?

0 Wall Street analysts have set twelve-month price targets for XOMA Royalty in the last year. Their average twelve-month price target is $60.60, suggesting a possible upside of 136.2%. HC Wainwright has the highest price target set, predicting XOMA will reach $97.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $35.00 for XOMA Royalty in the next year.
View the latest price targets for XOMA.

What is the current consensus analyst rating for XOMA Royalty?

XOMA Royalty currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XOMA, but not buy more shares or sell existing shares.
View the latest ratings for XOMA.

What other companies compete with XOMA Royalty?

Other companies that are similar to XOMA Royalty include XOMA, Zenas BioPharma, OPKO Health, Geron and Ironwood Pharmaceuticals. Learn More about companies similar to XOMA Royalty.

How do I contact XOMA Royalty's investor relations team?

XOMA Royalty's physical mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company's listed phone number is (510) 204-7200 and its investor relations email address is [email protected]. The official website for XOMA Royalty is www.xoma.com. Learn More about contacing XOMA Royalty investor relations.